AKT1 and hepatocellular carcinoma: MAPK-associated inhibitors have been used to treat HCC (85), but very few HCC patients benefited from this treatment (86), largely owing to the compensatory activation of other Ras-related pathways such as the AKT (87) and IGF/FGF (88) signaling pathways.